Sloan-Kettering Institute for Cancer Research v. Helmholtz-Zentrum fur Infektionsforschung Gmbh

Sloan-Kettering Institute for Cancer Research v. Helmholtz-Zentrum fur Infektionsforschung Gmbh

B.P.A.I. (2006)

Fitzpatrick Prevails in Interference On Behalf of Helmholtz-Zentrum fur Infektionsforschung Gmbh

Fitzpatrick, Cella prevailed in an interference between our client Helmholtz-Zentrum fur Infektionsforschung Gmbh, exclusive licensor to Bristol-Myers Squibb Company, and Sloan Kettering Institute for Cancer Research. The interference involved two cancer compounds, epothilone C and epothilone D. After obtaining senior party status in the preliminary motion phase, SKI recognized that it would not be able to antedate HZI’s dates of conception and actual reduction to practice, and as a result, SKI had to concede priority. Judgment has now been entered in favor of HZI.